Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ANIP NYSE:ANVS NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.95$8.70$7.21▼$20.46$2.07B0.733.70 million shs4.37 million shsANIPANI Pharmaceuticals$86.03$81.00$62.60▼$99.50$1.96B0.43315,458 shs572,948 shsANVSAnnovis Bio$1.94+0.3%$1.94$1.54▼$5.50$66.87M1.19893,620 shs958,337 shsSYRESpyre Therapeutics$86.63$78.04$14.51▼$102.06$7.62B3.021.80 million shs973,914 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+3.95%+2.64%+17.76%-2.61%-50.66%ANIPANI Pharmaceuticals+3.59%+3.30%+15.24%+15.93%+31.91%ANVSAnnovis Bio+0.52%+16.92%+3.75%-14.95%-18.70%SYRESpyre Therapeutics-2.54%-2.30%+25.26%+82.07%+458.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.95$8.70$7.21▼$20.46$2.07B0.733.70 million shs4.37 million shsANIPANI Pharmaceuticals$86.03$81.00$62.60▼$99.50$1.96B0.43315,458 shs572,948 shsANVSAnnovis Bio$1.94+0.3%$1.94$1.54▼$5.50$66.87M1.19893,620 shs958,337 shsSYRESpyre Therapeutics$86.63$78.04$14.51▼$102.06$7.62B3.021.80 million shs973,914 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+3.95%+2.64%+17.76%-2.61%-50.66%ANIPANI Pharmaceuticals+3.59%+3.30%+15.24%+15.93%+31.91%ANVSAnnovis Bio+0.52%+16.92%+3.75%-14.95%-18.70%SYRESpyre Therapeutics-2.54%-2.30%+25.26%+82.07%+458.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67119.74% UpsideANIPANI Pharmaceuticals 2.75Moderate Buy$107.3324.76% UpsideANVSAnnovis Bio 2.25Hold$13.50597.67% UpsideSYRESpyre Therapeutics 3.00Buy$95.8310.62% UpsideCurrent Analyst Ratings BreakdownLatest ANIP, ADMA, ANVS, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/23/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $135.006/18/2026ADMAADMA Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/16/2026SYRESpyre Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$100.006/15/2026SYRESpyre Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$98.00 ➝ $112.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.006/4/2026SYRESpyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.006/1/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M4.07$0.68 per share13.16$2.01 per share4.45ANIPANI Pharmaceuticals$883.37M2.22$10.29 per share8.36$24.03 per share3.58ANVSAnnovis BioN/AN/AN/AN/A$0.64 per shareN/ASYRESpyre Therapeutics$890K8,559.82N/AN/A$7.21 per share12.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6813.169.52N/A32.43%39.98%28.08%8/5/2026 (Estimated)ANIPANI Pharmaceuticals$78.34M$3.9521.789.93N/A9.98%27.51%10.02%8/14/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%8/18/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest ANIP, ADMA, ANVS, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AANIPANI PharmaceuticalsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93ANIPANI Pharmaceuticals1.063.122.52ANVSAnnovis BioN/A1.271.27SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ANIPANI Pharmaceuticals76.05%ANVSAnnovis Bio15.83%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ANIPANI Pharmaceuticals8.10%ANVSAnnovis Bio20.80%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableSYRESpyre Therapeutics7387.94 million74.14 millionOptionableANIP, ADMA, ANVS, and SYRE HeadlinesRecent News About These CompaniesInsider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $658,050.00 in StockJuly 3 at 6:21 AM | insidertrades.comSpyre Therapeutics Announces Grants of Inducement AwardsJuly 2 at 4:05 PM | globenewswire.comSpyre Therapeutics, Inc. $SYRE Stock Holdings Decreased by Pictet Asset Management Holding SAJuly 2 at 4:40 AM | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by AnalystsJuly 2 at 4:35 AM | americanbankingnews.comSpyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting DataJune 30 at 7:32 PM | seekingalpha.comIs SYRE Stock a Buy Now or a Wait-and-See Biotech Story TodayJune 29, 2026 | zacks.comSpyre Therapeutics Stock Outlook Hinges on 2026 Study CatalystsJune 29, 2026 | zacks.comSYRE and Spyre Ride New IBD Trends in Biotech Drug DesignJune 29, 2026 | zacks.comScott Burrows Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 28, 2026 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $1,306,950.00 in StockJune 27, 2026 | insidertrades.comBiotech ETF Index Surges 10% After RebalanceJune 25, 2026 | etftrends.comESpyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High After Analyst UpgradeJune 25, 2026 | americanbankingnews.comSpyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)June 24, 2026 | finance.yahoo.comMichael Thomas Henderson Sells 20,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 24, 2026 | insidertrades.comStifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)June 23, 2026 | theglobeandmail.comSpyre Therapeutics Inc SYREJune 18, 2026 | morningstar.comMAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)June 18, 2026 | theglobeandmail.comSpyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term StudyJune 18, 2026 | tipranks.comPerceptive Advisors LLC Buys 1,839,780 Shares of Spyre Therapeutics, Inc. $SYREJune 18, 2026 | marketbeat.comSpyre Therapeutics, Inc. $SYRE Stock Position Boosted by Commodore Capital LPJune 18, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)June 16, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026ANIP, ADMA, ANVS, and SYRE Company DescriptionsADMA Biologics NASDAQ:ADMA$8.95 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$8.93 -0.02 (-0.25%) As of 07/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.ANI Pharmaceuticals NASDAQ:ANIP$86.03 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$86.01 -0.02 (-0.02%) As of 07/2/2026 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Annovis Bio NYSE:ANVS$1.94 +0.01 (+0.26%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$1.95 +0.02 (+0.98%) As of 07/2/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Spyre Therapeutics NASDAQ:SYRE$86.63 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$85.40 -1.23 (-1.42%) As of 07/2/2026 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
